Hologic Launches its First Cart-Based Ultrasound System, SuperSonic™ MACH 40
10 Juillet 2020 - 07:01PM
Business Wire
Latest innovation expands portfolio of ultrasound
technologies with premium offering designed to enhance efficiency
and accuracy
Regulatory News:
SuperSonic Imagine (Paris:SSI):
Hologic, Inc. (Nasdaq: HOLX) announced today the U.S. launch of
the SuperSonic™ MACH 40 ultrasound system, expanding the Company’s
suite of ultrasound technologies with its first premium, cart-based
system. The new system features excellent image quality,
standard-setting imaging modes, and is designed to enhance
efficiency and accuracy.
“As the leader in breast imaging, we’re committed to delivering
insight-driven solutions that optimize patient care across the full
continuum of care for breast health – from screening to treatment,”
said Pete Valenti, Hologic’s Division President, Breast and
Skeletal Health Solutions. “With the addition of the SuperSonic
MACH 40 system, we’ve successfully built a comprehensive portfolio
of innovative, standard-setting breast ultrasound solutions
designed to better meet the needs of breast imagers. The SuperSonic
MACH 40 system embodies our commitment to delivering
future-oriented solutions and was designed to help healthcare
professionals reduce unnecessary biopsies by eliminating re-scans,
reducing lesion correlation time, and improving overall diagnostic
accuracy.”
The SuperSonic MACH 40 system leverages exclusive UltraFast™
imaging technology – inspired by cutting-edge graphics innovations
from the video gaming industry – to provide greater frame rates of
up to 20,000 images per secondi. The technology also enables
innovative imaging modes, without the trade-offs present in
conventional systems. This forward-thinking, powerful architecture
primes the system for future integrations and AI-driven
innovations.
The new system is further enhanced by exceptional B-mode imaging
technology, which helps improve diagnostic confidence thanks to
smoother images with reduced speckle, clearer images across all
tissue densities, and improved lesion conspicuity. It also features
the third generation of shear wave-based elastography technology,
ShearWave™ PLUS, which provides additional diagnostic information
that may help with patient management, including diagnostic workup
of breast lesions, lesion targeting during ultrasound-guided
biopsy, and lesion size measurement. Three innovative imaging modes
come together in TriVu™ imaging, where morphology, stiffness and
blood flow can all be analyzed simultaneously in the same
image.
“Hologic continues to expand its portfolio with the patient and
clinician in mind, and that’s apparent with the recent SuperSonic
Imagine acquisition and new innovations,” said Stacy Smith-Foley,
MD, Medical Director of The Breast Center at CARTI in Little Rock,
AR. “The result has been a consistently growing suite of tools that
truly complement each other and help me and my colleagues to
efficiently care for our patients on a day-to-day basis across the
entire breast health continuum.”
Clinicians performing precision-dependent ultrasound-guided
biopsies with the SuperSonic MACH 40 system can also enjoy enhanced
control with Needle PL.U.S. imaging, which enables visualization of
both the biopsy needle and anatomical structures in real time and
predicts the needle trajectory.
The SuperSonic MACH 40 system streamlines workflow with
intuitive design and enhanced comfort. Thanks to the SonicPad™
multi-touch trackpad, the new system helps physicians focus on
imaging without the distractions of unnecessary user movements,
thus enhancing workflow and increasing patient throughput.
The SuperSonic MACH 40 system is part of a growing portfolio of
ultrasound solutions resulting from Hologic’s recent acquisition of
SuperSonic Imagine, a pioneer in the field of ultrasound imaging.
For more information about the SuperSonic MACH 40 ultrasound
system, visit hologic.com/ultrasound/MACH-40
Forward-Looking
Statements
This news release may contain forward-looking information that
involves risks and uncertainties, including statements about the
use of Hologic products. There can be no assurance these products
will achieve the benefits described herein or that such benefits
will be replicated in any particular manner with respect to an
individual patient, as the actual effect of the use of the products
can only be determined on a case-by-case basis. In addition, there
can be no assurance that these products will be commercially
successful or achieve any expected level of sales. Hologic
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any such statements presented
herein to reflect any change in expectations or any change in
events, conditions or circumstances on which any such data or
statements are based.
This information is not intended as a product solicitation or
promotion where such activities are prohibited. For specific
information on what products are available for sale in a particular
country, please contact a local Hologic sales representative or
write to womenshealth@hologic.com.
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company
primarily focused on improving women’s health and well-being
through early detection and treatment. For more information on
Hologic, visit www.hologic.com.
Hologic, ShearWave, SonicPad, SuperSonic, The Science of Sure,
TriVu and UltraFast are trademarks and/or registered trademarks of
Hologic, Inc., and/or its subsidiaries in the United States and/or
other countries.
i Ultrafast Ultrasound Imaging, by Jeremy Bercoff (Published:
August 23 2011 DOI: 10.5772/19729)
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200710005426/en/
Media Contact: Jane Mazur
508.263.8764 (direct) 585.355.5978 (mobile)
jane.mazur@hologic.com
Investor Contact: Michael
Watts 858.410.8588 michael.watts@hologic.com
Contacts – Investor Relations NewCap Thomas Grojean
supersonicimagine@newcap.eu +33 44 71 94 94